Tuesday, 21 May 2019

You are here

Ten Contemporary Challenges Facing Lupus Treatment

A group of French researchers have pooled their interests to identify the challenges ahead in the management of patients with systemic lupus erythematosus (SLE). 

This introspective review puts forth the authors’ perceptions of the 10 most important contemporary challenges in the management of SLE. The paper represents the roundtable consensus of a multidisciplinary team of clinicians, pharmacists and researchers from a national centre for rare autoimmune and systemic diseases (Strasbourg, France).

The 10 main contemporary challenges in SLE include: 

  • T2T: favouring disease remission (or low disease activity).
  • Limiting the use of glucocorticoids.
  • Deriving more comprehensive tools for the evaluation of disease activity.
  • Developing more effective (and better tolerated) drugs (and more successful trials).
  • Dissecting the heterogeneity of the disease at the molecular and genetic levels.
  • Identifying relevant biomarkers for individualised treatment.
  • Managing fertility and pregnancy.
  • Managing comorbidities(e.g., cardiovascular risk, infections, osteoporosis).
  • Improving the network of care (the patients’ perspective).
  • Favouring a holistic approach (integrating fatigue, adherence to treatment, physical activity).

These 10 contemporary challenges in SLE may be considered as a roadmap for those involved in the daily care of patients with SLE, as well as for researchers who may wish to contribute to an improved management of this rare and complex disease.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Risk Score Predicts Thrombosis Recurrence in APS

A combination risk score helped predict recurrent thrombosis -- particularly arterial -- among patients with antiphospholipid syndrome (APS), an international study found.

Racial Disparities in Mortality Associated with Systemic Lupus Erythematosus

A Morbidity and Mortality Weekly Report on a registry of systemic lupus erythematosus (SLE) patients from two Georgia counties (Fulton and Dekalb) shows SLE mortality was 2-3 times higher compared to the general population, especially amongst blacks; notably deaths occurred sooner after diagnosis and at a mean age approximately 13 years younger.

Calcineurin Inhibitors in Anti-Synthetase Dermatomyositis ILD

A pilot treatment study of patients with anti-aminoacyl-tRNA synthetase antibody–positive polymyositis/dermatomyositis-associated interstitial lung disease (anti-ARS-PM/DM-ILD) shows therapy with glucocorticoids and calcineurin inhibitors (CNI) to be highly effective. 

Biomarkers Predict Thrombosis in Lupus

A composite risk score that included three biomarkers predicted thrombotic events among patients with systemic lupus erythematosus (SLE), a cross-sectional study found.

Monocyte Patrolling Contributes to Lupus Glomerulonephritis

Systemic lupus erythematosus (SLE) is an autoimmune disease with a propensity to develop glomerulonephritis (47-70%) or end-stage kidney disease despite therapy.

Hallmarks of the disease are the appearance of immune complexes (IC) containing autoreactive Abs and TLR-activating nucleic acids, whose deposition in kidney glomeruli is suspected to promote tissue injury and glomerulonephritis (GN).